By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Celgene International Sárl 

Route de Perreux 1

Boudry    2017  Switzerland
Phone: 41-32-729-85-00 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






Company News
Celgene International Sárl (CELG) Release: Results From Phase III Study (AML-001) Of VIDAZA® (Azacitidine For Injection) In Acute Myeloid Leukemia Presented At European Hematology Association 6/16/2014 10:46:25 AM
Celgene International Sárl (CELG) Release: Retrospective Analysis Of Overall Survival Adjusting For Patient Crossover In Phase III Study Of POMALYST®/IMNOVID® (Pomalidomide) In Previously Treated Multiple Myeloma Presented At EHA 6/16/2014 10:44:12 AM
Celgene International Sárl (CELG) Release: First-Of-Its-Kind Multinational Survey Confirms Psoriasis And Psoriatic Arthritis Patients Are Frequently Undertreated Or Not Treated At All 3/20/2014 10:07:58 AM
Celgene International Sárl (CELG) Release: ABRAXANE® Plus Gemcitabine Receives European Marketing Authorization For First-Line Treatment Of Patients With Metastatic Pancreatic Cancer 1/7/2014 8:42:12 AM
Celgene International Sárl (CELG) Release: Studies Evaluating REVLIMID® (Lenalidomide) In Lymphoma Presented At American Society of Hematology 12/11/2013 6:37:04 AM
Celgene International Sárl (CELG) Release: REVLIMID® (Lenalidomide)-Treated Patients With Deletion-5q MDS Who Achieve Transfusion-Independence Of At Least 26 Weeks And AML-Free Survival Associated With Cytogenetic Response 12/10/2013 10:14:07 AM
Celgene International Sárl (CELG) Release: Two Studies Highlight Retrospective Analyses Of Phase III Study Of POMALYST®/IMNOVID® (Pomalidomide) In Previously Treated Multiple Myeloma Patients Presented At American Society of Hematology 12/10/2013 7:17:21 AM
First Analysis Of Extended Dosing With Celgene International Sárl (CELG) Epigenetic Agent CC-486 In Patients With Higher-Risk Myelodysplastic Syndromes Presented At American Society of Hematology 12/9/2013 9:53:46 AM
Celgene International Sárl (CELG) Receives Positive CHMP Opinion For ABRAXANE® In Combination With Gemcitabine As Treatment For Patients With Metastatic Pancreatic Cancer 11/22/2013 6:31:12 AM
Celgene International Sárl (CELG) Release: Initial Phase 3 Results of the FIRST® Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (PTS) Ineligible for Stem Cell Transplantation (SCT) Accepted for Plenary Presentation at American Society of Hematology Annual Meeting 11/7/2013 10:13:27 AM
12345678910
//-->